Literature DB >> 21999547

Serotyping of Proteus mirabilis clinical strains based on lipopolysaccharide O-polysaccharide and core oligosaccharide structures.

W Kaca1, J Glenska, L Lechowicz, S Grabowski, A Brauner, M Kwinkowski.   

Abstract

The aim of this work was to serotype Proteus mirabilis urinary tract infection (UTI) strains based on chemically defined O-antigens with the use of two clinical collections from Sweden and Poland consisting of 99 and 24 UTI strains, respectively. A simple two-step serotyping scheme was proposed using enzyme immunoassay with heat-stable surface antigens of Proteus cells and immunoblotting with isolated lipopolysaccharides (LPSs). Using polyclonal anti-P. mirabilis rabbit antisera, 50 Swedish and 8 Polish strains were classified into serogroups O10, O38, O36, O30, O17, O23, O9, O40, O49, O27, O5, O13, O24, O14, and O33. From the Swedish strains, 10 belonged to serogroup O10 and five to each of serogroups O38, O36, and O9. Therefore, none of the O-serogroups was predominant. The majority of the serotyped clinical strains possess acidic O-antigens containing uronic acids and various acidic non-carbohydrate substituents. In immunoblotting, antisera cross-reacted with both O-antigen and core of LPSs. The core region of 19 LPSs bound a single serum, and that of 12 LPSs bound more than two sera. Following bioinformatic analysis of the available sequences, a molecular approach to the prediction of Proteus core oligosaccharide structures was proposed. The identification of the core type of P. mirabilis R110, derived from a serogroup O3 wild strain, using restriction fragments length polymorphism analysis of galacturonic acid transferase is shown as an example. In summary, the most frequent O-serogroups among P. mirabilis UTI stains were identified. The diversity of serological reactions of LPSs is useful for serotyping of P. mirabilis clinical isolates. A possible role of the acidic components of O-antigens in UTI is discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999547     DOI: 10.1134/S0006297911070169

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  6 in total

1.  Genetic diversity of the O antigens of Proteus species and the development of a suspension array for molecular serotyping.

Authors:  Xiang Yu; Agnieszka Torzewska; Xinjie Zhang; Zhiqiu Yin; Dominika Drzewiecka; Hengchun Cao; Bin Liu; Yuriy A Knirel; Antoni Rozalski; Lei Wang
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

2.  Genomic and Ecogenomic Characterization of Proteus mirabilis Bacteriophages.

Authors:  Diana R Alves; Jonathan Nzakizwanayo; Cinzia Dedi; Chara Olympiou; Aurélie Hanin; Witold Kot; Lars Hansen; Rene Lametsch; Cormac G M Gahan; Pascale Schellenberger; Lesley A Ogilvie; Brian V Jones
Journal:  Front Microbiol       Date:  2019-08-06       Impact factor: 5.640

3.  The prevailing O serogroups among the serologically differentiated clinical Proteus spp. strains in central Poland.

Authors:  Dominika Drzewiecka; Agata Palusiak; Małgorzata Siwińska; Agnieszka Zabłotni
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

4.  Development of a Phage Cocktail to Control Proteus mirabilis Catheter-associated Urinary Tract Infections.

Authors:  Luís D R Melo; Patrícia Veiga; Nuno Cerca; Andrew M Kropinski; Carina Almeida; Joana Azeredo; Sanna Sillankorva
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

5.  Detection of human antibodies binding with smooth and rough LPSs from Proteus mirabilis O3 strains S1959, R110, R45.

Authors:  J Gleńska-Olender; K Durlik; I Konieczna; P Kowalska; J Gawęda; W Kaca
Journal:  Antonie Van Leeuwenhoek       Date:  2017-09-09       Impact factor: 2.271

Review 6.  Proteus mirabilis Biofilm: Development and Therapeutic Strategies.

Authors:  Reham Wasfi; Samira M Hamed; Mai A Amer; Lamiaa Ismail Fahmy
Journal:  Front Cell Infect Microbiol       Date:  2020-08-14       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.